Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | |||||||||||||
| PMID | |||||||||||||
| Authors | Laura A. Vitale, Lawrence J. Thomas, Thomas O'Neill, Jenifer Widger, Laura Mills-Chen, Andrea Crocker, Colleen Patterson, Anna Wasiuk, Eric Forsberg, James Boyer, Crystal Sisson, Jeffrey Weidlick | ||||||||||||
| Title | CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1 | ||||||||||||
|
|||||||||||||
| URL | https://www.abstractsonline.com/pp8/#!/6812/presentation/2483 | ||||||||||||
| Abstract Text | AACR Annual Meeting 2019, Abstract 2392 | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CDX-527 | CDX527|CDX 527 | CD27 Antibody 3 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 134 | CDX-527 is a tetravalent human antibody targeting both CD27 and PD-L1 (CD274), which may lead to enhanced immune activation (AACR Annual Meeting 2019, Abstract 2392, PMID: 32451681). |
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | CDX-527 | Preclinical - Cell culture | Actionable | In a preclinical study, CDX-527 inhibited PD-1 signaling, and stimulated T cell response in culture (AACR Annual Meeting 2019, Abstract 2392). | detail... |